Navigation Links
Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
Date:4/27/2009

Next Safety, Inc. has developed the most effective pulmonary nicotine delivery device to help people quit smoking

JEFFERSON, N.C., April 27 /PRNewswire/ -- Matthew P. Bars, MS, CTTS, has joined Next Safety, Inc. (NSI) as chairman. In his smoking cessation work, he has appeared on the NBC Today Show several times, as well as the CBS Evening News with Dan Rather, ABC World News Tonight, CNBC and CNN.

Mr. Bars has a B.S. in Psychology, an M.S. in Clinical Psychology and is a member of the American Academy of Addiction Psychiatry. He is a consultant and key opinion-maker for many pharmaceutical, healthcare, and medical diagnostic companies and has been engaged in the treatment, management, and administration of nicotine addiction services since 1980.

Mr. Bars is a contributing editor to the National Cancer Institute's "Clearing the Air" stop-smoking publication. He is also the expert consultant and director for smoking cessation for the Fire Department of New York City and the co-developer of the "Tobacco Free with the New York FD" program. He is the current clinical director of the Palisades Medical Center's IQuit Smoking Program (an affiliate of the Columbia University New York Presbyterian Healthcare System and a director of the IQuit Smoking Consultation Service).

"I have worked against nicotine addiction for almost 30 years and I am excited to be working with a company that is poised to save lives with what I have named 'the Next Step' in nicotine replacement therapy," said Mr. Bars.

In human trials, utilizing the Next Safety Platform, the device was highly effective in the pulmonary delivery of nicotine and other drugs. The phase I trials included blood results that were independently measured by a leading laboratory at a major academic research institution. Participants reported significant psychoactive effects.

NSI's proprietary platform is a powerful new method for the pulmonary delivery of drugs; the small handheld device will allow the user to inhale nicotine vapor and other drugs from an air stream with a high degree of control and safety. The company's manufacturing partners for the production of its nicotine delivery device are large global companies with more than 150 combined international sites, including a number of FDA-approved manufacturing facilities in the US.

NSI has an agreement with a major US-based pharmaceutical company to supply pharmaceutical-grade nicotine. NSI expects the price of an equivalent amount of nicotine delivered by its device, as compared to the amount of nicotine delivered by a carton of cigarettes, to be less than 10% of the current average market price in the US.

In addition, NSI is testing other drugs that use its new pulmonary drug delivery platform for a number of leading pharmaceutical companies. These drugs include treatments for asthma, pulmonary infections, and the delivery of proteins to treat certain types of cancer as well as insulin and proteins for treating other conditions.

    Contact:

    Eric Hunter
    336-246-7700

http://www.nextsafety.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Next Safety, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition
2. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
3. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
4. TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009
5. DuPont Leader: Agriculture is Up to Global Productivity Challenge
6. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
7. Global Aviation Summit Explores Low-Carbon Flight
8. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
9. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
10. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
11. 3rd Global Jatrophaworld Training 2009... Set to Create and Build a Sustainable non-food Biodiesel Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
(Date:3/23/2017)... March 23, 2017  Agriculture technology company Cool Planet ... and note conversion to commercialize its Cool Terra and ... on developing products that are simultaneously profitable as well ... the last 18 months. This latest round of funding ... Partners. The company,s primary product, Cool ...
(Date:3/22/2017)... 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced ... U.K. Biobank and GSK to generate genetic sequence data from ... initiative will enable researchers to gain valuable insights to support ... range of serious and life threatening diseases. ... Genetic evidence has ...
(Date:3/22/2017)... , March 22, 2017  UBM and ... to announce their extended partnership and the third ... headlined by the 21 st Annual MassMEDIC ... taking place May 3-4, 2017. ... Technology Association (ADVAMED) President and CEO, Scott ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):